Eli Lilly’s oral weight loss drug may enter the European market as early as the second half of this year.

Glonghui, June 24｜Eli Lilly is accelerating the expansion of its global obesity treatment footprint. Patrik Jonsson, Executive Vice President of International Business at Eli Lilly, stated that after receiving regulatory approval in the US and UAE, Europe will be the next key market for the company’s product launches. Eli Lilly's oral weight loss drug is expected to be available in Europe as early as the second half of this year and at the latest by early 2027, and the company will replicate its US market strategy by promoting products via telemedicine platforms, e-commerce, and direct-to-consumer (DTC) channels. Unlike the US market, most obesity treatment costs in Europe are still primarily paid out-of-pocket by patients, with public healthcare systems offering relatively limited coverage for weight-loss drugs. Therefore, Eli Lilly plans to prioritize targeting the consumer market of those willing to pay out-of-pocket for weight-loss medication.